Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
Shenderov E, Boudadi K, Fu W, Wang H, Sullivan R, Jordan A, Dowling D, Harb R, Schonhoft J, Jendrisak A, Carducci MA, Eisenberger MA, Eshleman JR, Luo J, Drake CG, Pardoll DM, Antonarakis ES. Shenderov E, et al. Among authors: jendrisak a. Prostate. 2021 May;81(6):326-338. doi: 10.1002/pros.24110. Epub 2021 Feb 26. Prostate. 2021. PMID: 33636027 Free PMC article. Clinical Trial.
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES. Boudadi K, et al. Among authors: jendrisak a. Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19. Oncotarget. 2018. PMID: 29983880 Free PMC article.
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
Brown LC, Halabi S, Schonhoft JD, Yang Q, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Barnett ES, Carbone EA, Zhao JL, Healy P, Anand M, Gill A, Jendrisak A, Berry WR, Gupta S, Gregory SG, Wenstrup R, Antonarakis ES, George DJ, Scher HI, Armstrong AJ. Brown LC, et al. Among authors: jendrisak a. Clin Cancer Res. 2021 Jul 15;27(14):4077-4088. doi: 10.1158/1078-0432.CCR-20-3471. Epub 2021 Apr 5. Clin Cancer Res. 2021. PMID: 33820782 Free PMC article.
Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer.
Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Edwards M, Sangar S, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL. Friedlander TW, et al. Among authors: jendrisak a. J Urol. 2019 Oct;202(4):732-741. doi: 10.1097/JU.0000000000000393. Epub 2019 Sep 6. J Urol. 2019. PMID: 31216253
Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer.
Schonhoft JD, Zhao JL, Jendrisak A, Carbone EA, Barnett ES, Hullings MA, Gill A, Sutton R, Lee J, Dago AE, Landers M, Bakhoum SF, Wang Y, Gonen M, Dittamore R, Scher HI. Schonhoft JD, et al. Among authors: jendrisak a. Cancer Res. 2020 Nov 15;80(22):4892-4903. doi: 10.1158/0008-5472.CAN-20-1216. Epub 2020 Aug 19. Cancer Res. 2020. PMID: 32816908 Free PMC article.
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
Chalfin HJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, Chu YL, Richardson R, Krupa R, Anderson AKL, Wang Y, Dittamore R, Pal SK, Lara PN, Stein MN, Quinn DI, Steinberg SM, Cordes LM, Ley L, Mallek M, Sierra Ortiz O, Costello R, Cadena J, Diaz C, Gulley JL, Dahut WL, Streicher H, Wright JJ, Trepel JB, Bottaro DP, Apolo AB. Chalfin HJ, et al. Among authors: jendrisak a. Clin Cancer Res. 2021 Mar 1;27(5):1391-1398. doi: 10.1158/1078-0432.CCR-20-2891. Epub 2020 Dec 1. Clin Cancer Res. 2021. PMID: 33262136 Free PMC article.
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, Fleisher M, Dittamore R. Scher HI, et al. Among authors: jendrisak a. JAMA Oncol. 2016 Nov 1;2(11):1441-1449. doi: 10.1001/jamaoncol.2016.1828. JAMA Oncol. 2016. PMID: 27262168 Free PMC article.
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
McDaniel AS, Ferraldeschi R, Krupa R, Landers M, Graf R, Louw J, Jendrisak A, Bales N, Marrinucci D, Zafeiriou Z, Flohr P, Sideris S, Crespo M, Figueiredo I, Mateo J, de Bono JS, Dittamore R, Tomlins SA, Attard G. McDaniel AS, et al. Among authors: jendrisak a. BJU Int. 2017 Nov;120(5B):E30-E44. doi: 10.1111/bju.13631. Epub 2016 Sep 18. BJU Int. 2017. PMID: 27539393 Free PMC article.
16 results